Overactive bladder (OAB) and irritable bowel syndrome (IBS) aren't the sexiest indications in the drug development universe, but tens of millions of patients remain untreated or undertreated for the common, uncomfortable conditions. With that large unmet need in mind, Velicept Therapeutics Inc. recently closed the first tranche of a $21 million series B financing to advance an asset that could potentially address both.